Clinical Trial Update: Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is investigating whether intravenous Angiotensin II can reduce the incidence of cardiac-surgery-associated acute kidney injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Vasoplegia

Drugs mentioned

• Giapreza (Angiotensin II)

Snippet

Sponsor: Universität Münster | Conditions: Cardiac Surgery, Vasoplegia | Phase 3 | Status: RECRUITING